Gene therapy for bladder cancer

Lance C. Pagliaro

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalWorld Journal of Urology
Issue number2
StatePublished - 2000

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Gene therapy for bladder cancer'. Together they form a unique fingerprint.

Cite this